Phase II study of oral L-leucovorin, 120-hour fluorouracil infusion and carboplatin in advanced pancreatic cancer

Tumori

Volumn 82, Issue 6, 1996, Pages 573-575

  Colleoni, Marco ^a,b   Nelli, Patrizia ^a   Vicario, Giovanni ^a   Pancheri, Francesca ^a   Sgarbossa, Gigliola ^a   Manente, Paolo ^a  

^a City Hospital   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

carboplatin; fluorouracil infusion; oral levo leucovorin

Indexed keywords

CARBOPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL;

EID: 0030433157     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169608200611     Document Type: Article

References (21)

1. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J. Clin. Oncol., 10: 896-991, 1992.
2. André T., Lotz J.P., Boulec C., Azzouzi K., Houry S., Hannon L., See J.: Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann. Oncol., 7:173-178, 1996.
3. Ardalan B., Chua L., Tian E.: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J. Clin. Oncol., 9: 625-629, 1991.
4. Ardalan B., Singh G., Silberman H.: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J. Clin. Oncol., 6: 1053-1057, 1988.
5. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C.: Combination chemotherapy versus carboplatin or iproplatin followed by combination chemotherapy in stage IV non-small cell lung cancer. An Eastern Cooperative Oncology Group study. J. Clin. Oncol., 7: 1602-13, 1989.
6. Bukowsky R.M., Fleming T.R., MacDonald J.S., Oishi N., Taylor A., Baker L.H.: Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. Cancer, 71: 322-325, 1993.
7. Bunn P.A., Canetta R., Ozola R.F., Rozencweig M.: Carboplatin (JM8): Current perspectives and future directions. W.B. Saunders, Philadelphia, 1990.
8. Calvert A.H.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 48-56, 1989.
9. Gehan E.A.: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chron. Dis., 20: 346-353, 1961.
10. Kaye S.B.: Gemcitabine: current status of phase I and phase II trials. J. Clin. Oncol., 12: 1527-1531, 1994.
11. Kish J.A., Ensley J.F., Jacobs J.: A randomized trial of cisplatin + 5-fluorouracil infusion and 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer, 56: 2740-2745, 1985.
12. Klastersky J., Sculier J.P., Lacrox H.: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced NSCLC. J. Clin. Oncol., 8: 1556-1562, 1990.
13. Lionetto R., Pugliese V., Bruzzi P., Rosso R.: No standard treatment is available for advanced pancreatic cancer. Eur. J. Cancer, 31:882-887, 1995.
14. Moore M., Andersen J., Bums H., Tarasoff P., Green M., Casper E.: A randomized trial of gemcitabine versus 5FU as first-line therapy in advanced pancreatic cancer (Abst). Proc. Am. Soc. Clin. Oncol., 14: 473, 1995.
15. O'Connell M.J.: Current status of chemotherapy for advanced pancreatic and gastric cancer. J. Clin. Oncol., 3: 1032-1035, 1985.
16. Poorter R.L., Peters G.J., Bakker P.J.M., Taat C.W., Biermans-van Leeuwe D.M.J., Codacci-Pisanelli G., Noordhuis P., Oosting J., Veenhof C.H.N.: Intermittent continuous infusion of 5-fluorouracil and low dose oral leucovorin in patients with gastrointestinal cancer: relationship between plasma concentrations and clinical parameters. Eur. J. Cancer, 31A: 1465-1470, 1995.
17. Rothman H., Cantrell J.E., Lokich J.: Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. Cancer, 68:264-268, 1991.
18. Rougier P., Farba J.J., Ducrex M., Basile M., Pignon I.P.: Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann. Oncol., 4: 333-336, 1993.
19. Schabel F.M., Trader M.W., Laster W.E.: Cis-dichlorodiamminoplatinum II combination chemotherapy and cross-resistance status of tumors in mice. Cancer Treat. Rep., 63: 1459-1473, 1979.
20. Speer R.J., Lapid S., Ridgway H.: Cis-platinum diamminodichloride (PDD) in combination therapy of leukemia L1210. Weekly Med. Bull., 1: 103-109, 1971.
21. Wils J.A.: Chemotherapy in pancreatic cancer: a rational pursuit? Anti-cancer Drugs 2: 3-10, 1991.